BullFrog AI CEO Vin Singh joins Natalie Stoberman from the Proactive newsroom to share how the company is using artificial intelligence (AI) for drug development through a renewed collaboration with Johns Hopkins Applied Physics Laboratory.
Singh says BullFrog AI aims to reduce the time, costs, and risks associated with drug development by leveraging their bfLEAP proprietary AI platform. Singh explains the platform can identify new drug targets, provide insights, and help stratify patients for clinical trials in order increase the chances of success.
Contact DetailsProactive Investors
+1 347-449-0879
